Figures
Abstract
Coenzyme Q10 (CoQ10) is a potent lipophilic antioxidant in cell membranes and a carrier of electrons in the mitochondrial respiratory chain. We previously characterized the effects of varying severities of CoQ10 deficiency on ROS production and mitochondrial bioenergetics in cells harboring genetic defects of CoQ10 biosynthesis. We observed a unimodal distribution of ROS production with CoQ10 deficiency: cells with <20% of CoQ10 and 50–70% of CoQ10 did not generate excess ROS while cells with 30–45% of CoQ10 showed increased ROS production and lipid peroxidation. Because our previous studies were limited to a small number of mutant cell lines with heterogeneous molecular defects, here, we treated 5 control and 2 mildly CoQ10 deficient fibroblasts with varying doses of 4-nitrobenzoate (4-NB), an analog of 4-hydroxybenzoate (4-HB) and inhibitor of 4-para-hydroxybenzoate:polyprenyl transferase (COQ2) to induce a range of CoQ10 deficiencies. Our results support the concept that the degree of CoQ10 deficiency in cells dictates the extent of ATP synthesis defects and ROS production and that 40–50% residual CoQ10 produces maximal oxidative stress and cell death.
Citation: Quinzii CM, Tadesse S, Naini A, Hirano M (2012) Effects of Inhibiting CoQ10 Biosynthesis with 4-nitrobenzoate in Human Fibroblasts. PLoS ONE 7(2): e30606. https://doi.org/10.1371/journal.pone.0030606
Editor: Antoni L. Andreu, Hospital Vall d'Hebron, Spain
Received: October 19, 2011; Accepted: December 24, 2011; Published: February 16, 2012
Copyright: © 2012 Quinzii et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The project was supported by K23 HD065871 (CMQ) and 1R01 HD057543 (MH) from the Eunice Kennedy Shriver National Institute of Child Health & Human Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Introduction
Ubiquinone or coenzyme Q (CoQ) is a lipophilic molecule present in virtually all cell membranes. Essential for multiple metabolic processes, CoQ is required for antioxidant defenses and electron transport from complex I and II to complex III in the mitochondrial respiratory chain [1]–[3]. CoQ is synthesized within mitochondria and is composed of a benzoquinone ring and a polyprenyl side chain. The length of the isoprenoid in ubiquinone varies among species; the predominant form in human is composed of 10 isoprenyl units and is designated CoQ10. Current knowledge about CoQ biosynthetic pathway in eukaryotes is mainly derived from studies of S. cerevisiae [4], [5]. At least 10 complementation groups of Q mutant yeast have been identified [6]–[8]. Whereas the quinone ring is derived from tyrosine or phenylalanine, the isoprenoid side chain is generated by addition of isopentenyl diphosphate molecules, derived from the mevalonate pathway, to farnesyl diphosphate in multiple steps catalyzed by polyprenyl diphosphate synthase (in human, a heterotetramer of two protein subunits, PDSS1 and PDSS2) [9]. Decaprenyl diphosphate and para-hydroxybenzoate (PHB) are condensed in a reaction catalyzed by 4-hydroxybenzoate:polyprenyl transferase or COQ2, and the benzoate ring is then modified by at least six enzymes, which catalyze methylation, decarboxylation, and hydroxylation reactions to synthesize CoQ10 [4], [5], [10]. ADCK3 is a protein kinase involved in CoQ biosynthesis and its yeast homolog, Coq8p, is required for the formation or maintenance of the multisubunit Q-biosynthetic complex and phosphorylation of Coq3p, Coq5p, and Coq7p [11]–[16].
Although CoQ10 deficiency has been identified in more than 100 patients with a wide spectrum of phenotypes, the molecular genetic bases have been identified in a minority of the patients and the pathophysiological consequences of human CoQ10 deficiency at the cellular level remain largely unknown [17]–[19].
In previous studies, we investigated the consequences of varying degrees of CoQ10 deficiency on ROS production, mitochondrial functions, and cell viability in skin fibroblasts with CoQ10 deficiency due to different molecular defects including mutations in COQ2 [20], PDSS2 [21]–[23], ADCK3 (CABC1) [12], and COQ9 [24]. We reported that cultured fibroblasts with severe CoQ10 deficiency (<20% of normal) have marked bioenergetic defects without significant oxidative stress, whereas intermediate CoQ10 deficiency (30–45% of normal) causes moderate bioenergetic defects but marked increases in ROS production, lipid oxidation, and cell death [2], [3]. Not surprisingly, cells with mild CoQ10 deficiency (>60% of normal) did not show increased ROS production or oxidative damage. However, because we compared cultured fibroblasts with diverse molecular genetic defects, factors other than CoQ10 deficiency may have contributed to their differing in vitro phenotype. Therefore, to assess the role of CoQ10 level on mitochondrial bioenergetics impairment, oxidative stress, and cell death in a uniform genetic background, we treated multiple cell lines with increasing dosages of 4-nitrobenzoate, which inhibits 4-hydroxybenzoate:polyprenyltransferase (COQ2) leading to dose-dependent decreases of CoQ in mammalian cells without directly inducing oxidative stress or mitochondrial respiration impairment [25].
Methods
Cell culture
Mitochondrial bioenergetic and oxidative stress experiments were performed in 5 control skin fibroblasts cell lines with normal CoQ10 levels and in 2 skin fibroblasts cell lines with ADCK3 mutations, P1 (p.Y514C and p.T584del) and P2 (homozygous p.Q167LfxX36), previously demonstrated to have defects of ubiquinone biosynthesis, measured by incorporation of radiolabeled parahydroxybenzoate (14C-PHB) (450 Ci/mol) [2], [20].
Cells were grown in Dulbecco's minimum essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 5 ml MEM vitamins, 5 ml MEM non-essential amino acids, 1 ml fungizone, and 5 ml penicillin-streptomycin until 50% confluent.
Experiments were performed after 6 days of incubation in RPMI 1640 glucose-free medium with 10% regular FBS, 25 mM HEPES, 1.5 mM Glutamax, 25 mM galactose, 1 ml fungizone, and 5 ml penicillin-streptomycin supplemented with one of the following: 4 mM DMSO, 1 mM 4-NB, 2 mM 4-NB, 3 mM 4-NB, or 4 mM 4-NB. To demonstrate that the effects of 4 mM 4-NB were caused by CoQ10 deficiency rather than side effects of the compound, control cell lines were supplemented also with 4-NB+2 mM 4-HB and 4-NB+ 5 µM CoQ10 [25], [26].
We performed experiments in galactose-medium because we previously demonstrated that CoQ10 deficient fibroblasts do not manifest increased oxidative stress and cell death or reduced mitochondrial function when cultured in glucose-rich medium [3]. ADCK3 mutant skin fibroblasts manifest mitochondrial bioenergetics impairment and oxidative stress when cultured in galactose RPMI 1640 media with dialyzed FBS, but not in galactose RPMI media with undialyzed FBS because glucose in FBS allows anerobic glycolysis to maintain the cellular energy charge [2]. In contrast, the slow metabolism of galactose to glucose-1-phosphate is insufficient for glycolytic synthesis of ATP oxidative phosphorylation is impaired [27].
Medium was changed at day 1, 3 and 5, and cells were collected at day 7 [25]. 4-NB and 4-HB (Sigma-Aldrich, St. Louis MO, USA) were dissolved in DMSO and stored at −20°C in 0.1 M stock solutions. All other cell culture reagents were obtained from Invitrogen (Invitrogen Corp., Eugene, OR, USA).
All cell lines at passage 7–10 were cultured at least 3 times, therefore, each value in the results represents the mean of at least 3 measurements.
CoQ10 levels
CoQ10 in fibroblasts was extracted in hexane:ethanol mixture. The lipid component of the extract was separated by high-performance liquid chromatography (HPLC) on a reverse phase Symmetry® C18 3.5 mm, 4.6×150 mm column (Waters), using a mobile phase consisting of methanol, ethanol, 2-propanol, acetic acid (500∶500∶15∶15) and 50 mM sodium acetate at a flow rate of 0.9 ml/min. The electrochemical detection system consisted of an ESA Coulochem III with a guard cell (upstream of the injector) at +900 mV, conditioning cell at 600 mV (downstream of the column), followed by the analytical cell at +500 mV. CoQ10 concentration was estimated by comparison of the peak area with those of standard solutions of known concentrations [26].
Adenine nucleotides levels
To determine levels of adenine nucleotides, cells were washed in ice-cold phosphate-buffered saline (PBS) and then collected in ice-cold 0.5 M perchloric acid using a scraper. After centrifugation at 3,000 g for 3 min at 4°C, pellets were suspended in 200 µl of ice-cold 0.5 M perchloric acid, vortexed for 30 s, and centrifuged at 11,000 g for 10 min at 4°C. The pellets were stored at −80°C for protein measurement. Adenine nucleotides in supernatants were measured in an Alliance HPLC (Waters Corporation, Milford, MA, USA) with an Alltima C18-NUC HPLC reverse-phase column (Alltech Associates, Deerfield, IL, USA) [3]. Adenine nucleotide levels were expressed in nmol/mg protein [26].
Mitochondrial membrane potential
To estimate mitochondrial membrane potential, control and mutant cells were exposed to tetramethylrhodamine ethyl ester (TMRE) (Molecular Probes, Invitrogen Corp., Eugene, OR, USA). Approximately 1×106 cells were trypsinized, incubated with TMRE for 20 min at 37°C, washed twice with PBS, re-suspended in 500 µl of PBS and kept in ice.
Cytofluorometric analysis of stained cells was performed on a FACSCalibur. Data were acquired using Cell Pro Quest and analyzed using Flowjo software (Becton Dickinson, NJ, USA) [2].
Oxidative stress analyses
To estimate production of ROS, control and mutant cells were exposed to MitoSOX Red, a fluorochrome specific for anion superoxide produced in the inner mitochondrial compartment (Molecular Probes, Invitrogen Corp., Eugene, OR, USA). Approximately 1×106 cells were trypsinized, incubated with MitoSox for 20 min at 37°C, washed twice with PBS and resuspended in 500 µl of PBS. Cytofluorometric analysis was performed on a FACSCalibur. Data were acquired using Cell Pro Quest and analyzed using Flowjo software (Becton Dickinson, NJ, USA) [3].
To assess oxidative damage, we assessed lipid peroxidation (LPO) after 4 mM 4-NB supplementation. For LPO measurements, confluent cells were collected in PBS from 15 cm plates using scrapers. After centrifugation at 3,000 g for 5 min, cells were suspended in 20 mM Tris–HCl buffer, pH 7.4, containing 5 mM butylated hydroxytoluene, and sonicated to lyse the cell. To remove large particles, the samples were centrifuged at 3,000 g for 10 min at 4°C. Aliquots of the supernatants were either stored at −80°C for total protein determination or used for LPO. Bioxytech LPO-568 assay kit was used to determine both malondialdehyde (MDA) and 4-hydroxyalkenals (4HE) (Oxis International, Foster City, CA, USA). Concentrations of LPO were normalized per mg protein [3].
Cell death studies
Cell viability was monitored by trypan blue exclusion. Numbers of living and dead cells were determined using the Countess Automated Cell Counter (Invitrogen). Healthy nuclei from viable cells appeared round and phase bright, whereas nuclei from dead or dying cells appeared blue and irregularly shaped. All cells were counted and results were expressed as the ratio of living versus total cells.
Statistical analysis
Control data are expressed as the mean ± standard deviation (SD) of 5 different normal fibroblast lines each analyzed in triplicate. Patients' data are expressed as the mean ± SD of triplicates experiments. Unpaired Student's T test with Welch correction was used. A p-value <0.05 was considered to be significant.
Results
CoQ10 level
Baseline levels of CoQ10 were reduced in ADCK3 mutant P1 (63%) and P2 (51%) relative to control fibroblasts (n = 5). Control and P2 fibroblasts showed decreased CoQ10 levels after 4 mM 4-NB supplementation and trends towards decreased levels after 1 mM, 2 mM, and 3 mM 4-NB treatment. In contrast, P1 fibroblasts showed a trend towards reduced CoQ10 levels after 1–4 mM 4-NB supplementation (Fig. 1).
CoQ10 levels are nmol/mg-protein (*P<0.05 vs. controls).
Co-treatment of control fibroblasts with 4 mM 4-NB and 2 mM 4-HB completely restored CoQ10 levels (Fig. 2) . Co-treatment of control fibroblasts with 4 mM 4-NB and 5 µM CoQ10 significantly increased levels of CoQ10 (Fig. 3).
The values are nmol/mg-protein (***P<0.001).
The values are nmol/mg-protein (***P<0.001).
Adenine nucleotide levels
ATP level was significantly decreased in controls and P2 fibroblasts after 1 mM, 2 mM, 3 mM, and 4 mM 4-NB supplementation (Fig. 4A). P1 fibroblasts showed a trend towards reduction in ATP levels after 1–4 mM 4-NB supplementation (Fig. 4A). Control and P2 fibroblasts showed significant decreases in ATP/ADP ratio after 4 mM of 4-NB supplementation and trends towards decreased levels after 1 mM, 2 mM, and 3 mM 4-NB treatment (Fig. 4B). Co-treatment of control fibroblasts with 4 mM 4-NB and 2 mM 4-HB completely restored ATP level and ATP/ADP ratio (Fig. 5A and B).
The values are nmol/mg-protein, P1 and P2 after 4 mM DMSO treatment. (* P<0.05 vs. controls; **P<0.01 vs. controls; ***P<0.001 vs. controls).
The values are nmol/mg-protein (** P<0.01 vs. controls; ***P<0.001).
Mitochondrial membrane potential
With 1 mM, 2 mM, and 3 mM 4-NB treatment, TMRE staining of control fibroblast was not significantly altered indicating stable mitochondrial membrane potential (ΔΨm), but a trend towards increased TMRE staining was observed with 4 mM 4-NB (Fig. 6). In contrast, after 2 mM, 3 mM, and 4 mM 4-NB supplementation, P1 and P2 cells revealed increased TMRE staining (Fig. 6). Co-treatment of control fibroblasts with 4 mM 4-NB and 2 mM 4-HB did not significantly alter TMRE intensity (Fig. 7).
The values are expressed as percentage of controls, P1 and P2 after 4 mM DMSO treatment. (* P<0.05 vs. controls;***P<0.001 vs. controls).
The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO.
Oxidative stress analyses
Control fibroblasts showed significantly increased MitoSox staining after 3 mM and 4 mM 4-NB treatment while P1 and P2 fibroblasts showed significantly increased MitoSox staining after 2 mM, 3 mM, and 4 mM 4-NB treatment (Fig. 8A). Control fibroblasts treated with 4 mM 4-NB and 2 mM 4-HB showed significantly less MitoSox staining than cells treated with 4 mM 4-NB only (Fig. 9A).
The values are expressed as percentage of controls, P1 and P2 after 4 mM DMSO treatment. (***P<0.001 vs. controls).
The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO (** P<0.01).
Lipid peroxidation (LPO) was slightly increased in controls, P1 and P2 fibroblasts after 4 mM of 4-NB treatment (Fig. 8B). Control fibroblasts treated with 4 mM 4-NB and 2 mM 4-HB showed significantly less LPO than cells treated with only 4 mM 4-NB (Fig. 9B).
MitoSox staining of control fibroblasts treated with 4 mM 4-NB and 5 µM CoQ10 was not significantly different than staining in cells treated with 4 mM 4-NB only (Fig. 10).
The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO (** P<0.01).
Cell death studies
Control fibroblasts showed significantly decreased cell viability after 3 mM 4-NB and 4 mM 4-NB while P1 and P2 cells showed decreased cell viability after 1 mM, 2 mm, 3 mM and 4 mM 4-NB treatments (Fig. 11).
The values are expressed as percentage of controls, P1 and P2 after 4 mM DMSO treatment. (* P<0.05 vs. controls; ** P<0.01 vs. controls).
Cell viability was normalized in control fibroblasts after co-treatment with 4 mM of 4-NB and 2 mM 4-HB (Fig. 12), but not after co-treatment with 4 mM 4-NB and 5 µM CoQ10 (Fig. 13).
The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO.
The values are expressed as percentage of the control skin fibroblasts after 4 mM DMSO. (* P<0.05 vs. controls; ** P<0.01 vs. controls).
Discussion
Although a growing number of patients with CoQ10 deficiency due to a variety of mutations in CoQ10 biosynthetic genes has been reported [18], the pathophysiology of this syndrome is not well understood. Previous studies in human fibroblasts with decreased levels of CoQ10 indicated that different mechanisms might be involved. Studying cultured fibroblasts from two siblings with infantile-onset CoQ10-deficiency of unknown genetic etiology, Geromel and colleagues found mild respiratory chain defects without evidence of increased superoxide anions, lipid peroxidation, or apoptosis-mediated cell death [28]. We observed similar abnormalities in fibroblasts carrying mutations in COQ9 and PDSS2 [2], [3].
In contrast, Lopez-Martin and colleagues showed that fibroblasts from a patient with a homozygous COQ2 mutation require uridine to maintain cell growth and proposed that deficiency of CoQ10 impaired pyrimidine biosynthesis due to dependence of dihydro-orotate dehydrogenase on ubiquinol [29]. In the same mutant COQ2 cell lines, as well as in other two cell lines with CoQ10 deficiency and unknown molecular defects, evidence of autophagy and oxidative stress has been observed [22]. More recently the same group showed evidence of increase ROS production and autophagy in a cellular model of secondary CoQ10 deficiency due to the m.3243A>G mutation [30]. Intriguingly, ultrastructural evidence of autophagy has also been found in kidney of mice with a homozygous mutation in Pdss2 [31]. Rapid improvements with supplemental CoQ10 or the antixoxidant probucol suggest that autophagy might be triggered by oxidative stress [32], [33].
Our previous studies of cells lines harboring COQ2 mutations have indicated that CoQ10 level correlates with the production of ROS, and that oxidative stress plays an important role in the demise of COQ2 mutant fibroblasts by activating cell-death related pathways, which are averted by antioxidant supplementation [3], [26]. Based on these observations, we hypothesized that the degree of CoQ10 deficiency in fibroblasts correlates with increased ROS production and cell death, independently of the primary molecular defect. In several mammalian cell lines other than human skin fibroblasts, 4-NB has been shown to decrease CoQ levels without any apparent direct toxic effects, in particular without inducing oxidative stress [25].
Here, we showed in control skin fibroblasts that pharmacological inhibition of COQ2 by 4-NB, leading to 40–50% residual CoQ10, is associated with increased oxidative stress and reduced viability, together with moderately decreased ATP levels and ATP/ADP ratio, similar to our observations in 3 different cell lines carrying mutations in COQ2.
Moreover, P1 and P2 ADCK3 mutant cells, which have 51–63% residual CoQ10, do not show signs of oxidative stress at baseline, but showed significant increases in ROS (indicated by MitoSox staining) when they reached 40–50% residual CoQ10 levels, which occurs, not surprisingly, after lower doses (2–4 mM) of 4-NB than in control cell lines (4 mM 4NB). Intriguingly, wild-type control and ADCK3 mutant cells reacted differently to 4-NB treatment. In control skin fibroblasts, we observed that only after maximum (4 mM) 4-NB treatment, CoQ10 content decreased significantly with proportional reductions in ATP level, whereas ROS production and trypan blue staining (indicating cell death) increased significantly after only 3 mM 4-NB. In cells with ADCK3 mutations and decreased ubiquinone at baseline, 4-NB rapidly induced further reductions in CoQ10 levels, which plateaued at 40% of normal. Decreased CoQ10 concentration was associated with increased MitoSox and TMRE (indicating increased mitochondrial membrane potential) staining, and with slightly reduced cell viability while ATP levels were only mildly decreased. ATP/ADP ratio decreased starting from 1 mM 4-NB in both controls and mutant cells. Unexpectedly, we were unable to reduce CoQ10 levels below 40% of control mean, even in P1 and P2 cells, which had baseline CoQ10 deficiency. A pilot experiment of a control cell line treated with 8 mM 4-NB produced massive and irreversible cell death (data not shown), thus, higher doses of the compound could not be used to further decrease CoQ biosynthesis. The effects of the treatment were less prominent but were observed more rapidly in mutant cell lines relative to controls In support of variable response of cell lines to 4-NB are published observations that a human hepatocyte cell line (C3A cells) were less responsive to 4-NB-mediated decreases in CoQ as compared to rodent cell lines [25].
On one hand, CoQ10 deficiency appears to be deleterious in 4-NB treated fibroblasts because rescue by co-treatment of cells with 4-HB and 4-NB normalized CoQ10 levels, bioenergic defects, and oxidative stress. On the other hand, the compound may have toxic effects in addition to inhibition of CoQ biosynthesis because CoQ10 co-treatment did not rescue 4-NB effects and because of a floor-effect of 4-NB, which did not decrease CoQ10 level below 40% of normal. Failure of CoQ10 supplementation to rescue 4-NB toxicity is unlikely be due to inadequate penetration ubiquinone into mitochondria because we previously observed that incubation of ubiquinone-deficient fibroblasts with 5 µM CoQ10 for 1 week increases ATP levels and ATP/ADP ratios significantly, indicating normalization of the bioenergetic status and mitochondrial functions [2], [3].
We also reported that in both control and mutant cells, mitochondrial membrane potential (ΔΨm) was not reduced by low CoQ10 content, but rather ΔΨm appeared to increase proportionally with increased ROS production and with decreased ATP levels and ATP/ADP ratios, supporting the hypothesis that early mitochondrial hyperpolarization might trigger mitochondrial ROS formation [2]. It is possible that the mitochondrial membrane potential is enhanced by the F(1)F(0) ATPase operating in ‘reverse’ mode, as suggested by other in vitro models of mitochondrial respiratory chain defects [34], [35].
Thus, our work in human skin fibroblasts with pharmacologically induced defects of ubiquinone biosynthesis have confirmed that increased ROS production contributes to the pathomechanism of CoQ10 deficiency associated with inhibition of COQ2 and that partial CoQ10 deficiency (40–50% residual) is associated with increased ROS production, hyperpolarization, and cell death compared to CoQ10 defiency that is mild (>50% of normal) or severe (<30% of normal) [2], [3].
Our observations of deleterious oxidative stress in ubiquinone-deficient human fibroblasts are supported by studies of other in vitro and in vivo models of CoQ deficiency. ROS production was enhanced in the coq10 and coq2 mutant S. cerevisiae [36], [37] while coq7 and coq2 mutant S. pombe displayed hypersensitivity to hydrogen peroxide and a requirement for antioxidants for growth on minimal medium indicating a key pathogenic role of oxidative stress in yeast models of CoQ deficiency [38], [39]. RNAi of coq-1,coq-2, and coq-3 in C. elegans GABA neurons led to activation of cell death pathway featuring elements of apoptosis and necrosis [40], while, in C. elegans low CoQ levels causing respiratory chain defects was associated with low ROS production and life span extension [41]. Apoptosis was also observed in embryos of embryonically lethal coq7 defective mice [42]; and intracellular superoxide was significantly elevated in HL-60 cells treated with p-aminobenzoate, an inhibitor of COQ2 [43]. Furthermore, as noted above, the rapid improvement of Pdss2 mutant mice with CoQ10 or probucol supplementation support the hypothesized role of increased ROS production in the pathogenesis of CoQ deficiency.
Our findings provide insights into the pathomechanisms underlying primary CoQ deficiency by demonstrating that the degree of bioenergetic defect and ROS production are related to the level of ubiquinone. Thus, depending on the severity of CoQ10 deficiency, biochemical targets for therapy may vary and may be relevant to other mitochondrial respiratory chain disorders. Moreover, the results may be germane to the pathogenesis and therapies of other neurodegenerative diseases with mitochondrial dysfunction.
Acknowledgments
The authors thank Drs. Meriem Tazir, Clotilde Lagier-Tourenne, and Michel Koenig for providing skin fibroblast from patient 2; Dr. David Lynch for referring patient 1; and Dr. Luis Carlos Lopez for reviewing the manuscript.
Author Contributions
Conceived and designed the experiments: CMQ MH. Performed the experiments: CMQ AN ST. Analyzed the data: CMQ AN MH. Contributed reagents/materials/analysis tools: CMQ ST AN MH. Wrote the paper: CMQ AN MH.
References
- 1. Bentinger M, Tekle M, Dallner G (2010) Coenzyme Q–biosynthesis and functions. Biochem Biophys Res Commun 396: 74–79.
- 2. Quinzii CM, Lopez LC, Gilkerson RW, Dorado B, Coku J, et al. (2010) Reactive oxygen species, oxidative stress, and cell death correlate with level of CoQ10 deficiency. FASEB J 24: 3733–3743.
- 3. Quinzii CM, Lopez LC, Von-Moltke J, Naini A, Krishna S, et al. (2008) Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J 22: 1874–1885.
- 4. Tran UC, Clarke CF (2007) Endogenous synthesis of coenzyme Q in eukaryotes. Mitochondrion 7: SupplS62–71.
- 5. Kawamukai M (2009) Biosynthesis and bioproduction of coenzyme Q10 by yeasts and other organisms. Biotechnol Appl Biochem 53: 217–226.
- 6. Barros MH, Johnson A, Gin P, Marbois BN, Clarke CF, et al. (2005) The Saccharomyces cerevisiae COQ10 gene encodes a START domain protein required for function of coenzyme Q in respiration. J Biol Chem 280: 42627–42635.
- 7. Johnson A, Gin P, Marbois BN, Hsieh EJ, Barros MH, et al. (2005) COQ9, a new gene required for the biosynthesis of coenzyme Q in Saccharomyces cerevisiae. J Biol Chem 280: 397–404.
- 8. Tzagoloff A, Dieckmann CL (1990) PET genes of Saccharomyces cerevisiae. Microbiol Rev 54: 211–225.
- 9. Saiki R, Nagata T, Kainou T, Matsuda H, Kawamukai M (2005) Characterization of solanesyl and decaprenyl diphosphate synthases in mice and humans. FEBS J 272: 5606–5622.
- 10. Gin P, Hsu AY, Rothman SC, Jonassen T, Lee PT, et al. (2003) The Saccharomyces cerevisiae COQ6 gene encodes a mitochondrial flavin-dependent monooxygenase required for coenzyme Q biosynthesis. J Biol Chem 278: 25308–25316.
- 11. Do TQ, Hsu AY, Jonassen T, Lee PT, Clarke CF (2001) A defect in coenzyme Q biosynthesis is responsible for the respiratory deficiency in Saccharomyces cerevisiae abc1 mutants. J Biol Chem 276: 18161–18168.
- 12. Lagier-Tourenne C, Tazir M, Lopez LC, Quinzii CM, Assoum M, et al. (2008) ADCK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am J Hum Genet 82: 661–672.
- 13. Mollet J, Delahodde A, Serre V, Chretien D, Schlemmer D, et al. (2008) CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet 82: 623–630.
- 14. Tauche A, Krause-Buchholz U, Rodel G (2008) Ubiquinone biosynthesis in Saccharomyces cerevisiae: the molecular organization of O-methylase Coq3p depends on Abc1p/Coq8p. FEMS Yeast Res 8: 1263–1275.
- 15. Xie LX, Hsieh EJ, Watanabe S, Allan CM, Chen JY, et al. (2011) Expression of the human atypical kinase ADCK3 rescues coenzyme Q biosynthesis and phosphorylation of Coq polypeptides in yeast coq8 mutants. Biochim Biophys Acta 1811: 348–360.
- 16. Padilla S, Tran UC, Jimenez-Hidalgo M, Lopez-Martin JM, Martin-Montalvo A, et al. (2009) Hydroxylation of demethoxy-Q6 constitutes a control point in yeast coenzyme Q6 biosynthesis. Cell Mol Life Sci 66: 173–186.
- 17.
Emmanuele V, Quinzii C, Lopez LC, Berardo A, Naini A, et al. (2011) Clinical and genetic heterogeneity of coenzyme Q10 deficiency; a study of 76 patients. submitted.
- 18. Quinzii CM, Hirano M (2010) Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev 16: 183–188.
- 19. Rahman S, Clarke CF, Hirano M (2011) 176th ENMC International Workshop: Diagnosis and treatment of coenzyme Q(10) deficiency. Neuromuscul Disord. in press.
- 20. Quinzii C, Naini A, Salviati L, Trevisson E, Navas P, et al. (2006) A Mutation in Para-Hydroxybenzoate-Polyprenyl Transferase (COQ2) Causes Primary Coenzyme Q10 Deficiency. Am J Hum Genet 78: 345–349.
- 21. Lopez LC, Schuelke M, Quinzii CM, Kanki T, Rodenburg RJ, et al. (2006) Leigh syndrome with nephropathy and CoQ10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet 79: 1125–1129.
- 22. Rodriguéz-Hernandez A, Cordero MD, Salviati L, Artuch R, Pineda M, et al. (2009) Coenzyme Q deficiency triggers mitochondrial degradation by mitophagy. Autophagy 5: 19–32.
- 23. Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, et al. (2007) COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 18: 2773–2780.
- 24. Duncan AJ, Bitner-Glindzicz M, Meunier B, Costello H, Hargreaves IP, et al. (2009) A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease. Am J Hum Genet 84: 558–566.
- 25. Forsman U, Sjoberg M, Turunen M, Sindelar PJ (2010) 4-Nitrobenzoate inhibits coenzyme Q biosynthesis in mammalian cell cultures. Nat Chem Biol 6: 515–517.
- 26. Lopez LC, Quinzii CM, Area E, Naini A, Rahman S, et al. (2010) Treatment of CoQ(10) deficient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: time- and compound-dependent effects. PLoS One 5: e11897.
- 27. Robinson BH, Petrova-Benedict R, Buncic JR, Wallace DC (1992) Nonviability of cells with oxidative defects in galactose medium: a screening test for affected patient fibroblasts. Biochem Med Metab Biol 48: 122–126.
- 28. Geromel V, Kadhom N, Ceballos-Picot I, Chretien D, Munnich A, et al. (2001) Human cultured skin fibroblasts survive profound inherited ubiquinone depletion. Free Radic Res 35: 11–21.
- 29. Lopez-Martin JM, Salviati L, Trevisson E, Montini G, DiMauro S, et al. (2007) Missense mutation of the COQ2 gene causes defects of bioenergetics and de novo pyrimidine synthesis. Hum Mol Genet 16: 1091–1097.
- 30. Cotán D, Cordero MD, Garrido-Maraver J, Oropesa-Avila M, Rodriguez-Hernandez A, et al. (2011) Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J. in press.
- 31. Peng M, Jarett L, Meade R, Madaio MP, Hancock WW, et al. (2004) Mutant prenyltransferase-like mitochondrial protein (PLMP) and mitochondrial abnormalities in kd/kd mice. Kidney Int 66: 20–28.
- 32. Falk MJ, Polyak E, Zhang Z, Peng M, King R, et al. (2011) Probucol ameliorates renal and metabolic sequelae of primary CoQ deficiency in Pdss2 mutant mice. EMBO Mol Med 3: 410–427.
- 33. Saiki R, Lunceford AL, Shi Y, Marbois B, King R, et al. (2008) Coenzyme Q10 supplementation rescues renal disease in Pdss2kd/kd mice with mutations in prenyl diphosphate synthase subunit 2. Am J Physiol Renal Physiol 295: F1535–1544.
- 34. McKenzie M, Liolitsa D, Akinshina N, Campanella M, Sisodiya S, et al. (2007) Mitochondrial ND5 gene variation associated with encephalomyopathy and mitochondrial ATP consumption. J Biol Chem 282: 36845–36852.
- 35. Abramov AY, Smulders-Srinivasan TK, Kirby DM, Acin-Perez R, Enriquez JA, et al. (2010) Mechanism of neurodegeneration of neurons with mitochondrial DNA mutations. Brain 133: 797–807.
- 36. Busso C, Bleicher L, Ferreira-Junior JR, Barros MH (2010) Site-directed mutagenesis and structural modeling of Coq10p indicate the presence of a tunnel for coenzyme Q6 binding. FEBS Lett 584: 1609–1614.
- 37. Davidson JF, Schiestl RH (2001) Mitochondrial respiratory electron carriers are involved in oxidative stress during heat stress in Saccharomyces cerevisiae. Mol Cell Biol 21: 8483–8489.
- 38. Miki R, Saiki R, Ozoe Y, Kawamukai M (2008) Comparison of a coq7 deletion mutant with other respiration-defective mutants in fission yeast. FEBS J 275: 5309–5324.
- 39. Uchida N, Suzuki K, Saiki R, Kainou T, Tanaka K, et al. (2000) Phenotypes of fission yeast defective in ubiquinone production due to disruption of the gene for p-hydroxybenzoate polyprenyl diphosphate transferase. J Bacteriol 182: 6933–6939.
- 40. Earls LR, Hacker ML, Watson JD, Miller DM 3rd (2010) Coenzyme Q protects Caenorhabditis elegans GABA neurons from calcium-dependent degeneration. Proc Natl Acad Sci U S A 107: 14460–14465.
- 41. Rodriguez-Aguilera JC, Gavilan A, Asencio C, Navas P (2005) The role of ubiquinone in Caenorhabditis elegans longevity. Ageing Res Rev 4: 41–53.
- 42. Nakai D, Shimizu T, Nojiri H, Uchiyama S, Koike H, et al. (2004) coq7/clk-1 regulates mitochondrial respiration and the generation of reactive oxygen species via coenzyme Q. Aging Cell 3: 273–281.
- 43. González-Aragón D, Burón MI, López-Lluch G, Herman MD, Gómez-Diáz C, et al. (2005) Coenzyme Q and the regulation of intracellular steady-state levels of superoxide in HL-60 cells. Biofactors 25: 31–41.